10-Q: Longeveron Inc. Reports Q1 2025 Financial Results; Cites Cash Runway Concerns

Sentiment:

Quarterly Report 8 May 2025 4:00 PM

Longeveron Inc. reports a net loss of $5.0 million for Q1 2025 and expresses concerns about its cash runway, anticipating the need for additional funding by late Q3 2025.

Delay expectedWhile enrollment completion was initially targeted for the end of 2024, given the relatively small patient population, clinical trial enrollment timing for rare diseases like HLHS is difficult to predict and we anticipate full enrollment will be completed prior to the end of the second quarter of 2025.

Capital raiseThe company anticipates needing additional funding by late Q3 2025.The company intends to seek additional financing/capital raises/non-dilutive funding options to support them.There can be no assurance the Company will be able to attain future financing at terms favorable to the Company or at all.

Worse than expectedThe company's net loss increased from $4.1 million to $5.0 million year-over-year.The company's revenues decreased from $0.548 million to $0.381 million year-over-year.The company anticipates needing additional funding by late Q3 2025.There is substantial doubt about the company's ability to continue as a going concern.

Summary

Longeveron Inc. reported a net loss of $5.0 million for the three months ended March 31, 2025, compared to a net loss of $4.1 million for the same period in 2024.
The company's cash and cash equivalents were $14.3 million as of March 31, 2025.
Longeveron anticipates its existing cash will fund operations into late Q3 2025 and plans to seek additional financing.
Revenues for Q1 2025 were $0.381 million, a decrease from $0.548 million in Q1 2024, primarily due to lower Bahamas Registry Trial revenue.
Research and development expenses increased to $2.5 million in Q1 2025 from $2.2 million in Q1 2024.
The company is focused on advancing its HLHS and Alzheimer's disease programs, with a potential BLA filing for HLHS in 2026 if the ELPIS II trial is successful.
Longeveron is seeking partnership opportunities and non-dilutive funding for its Alzheimer's disease program.
There is substantial doubt about the company's ability to continue as a going concern without raising additional funds.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to increasing losses, declining revenue, and concerns about the company's cash runway and ability to continue as a going concern. However, positive FDA interactions and ongoing clinical trials provide some optimism.

Positives

The FDA granted Regenerative Medicine Advanced Therapeutics (RMAT) Designation and Fast Track designation to Lomecel-B (laromestrocel) for the treatment of mild AD.
The company had a positive Type B meeting with the FDA supporting the advancement of Lomecel-B (laromestrocel) as a potential treatment for mild AD.
The company had a positive Type C meeting with the FDA supporting the advancement of Lomecel-B (laromestrocel) for HLHS.
The ELPIS I trial showed 100 percent transplant-free survival in children up to 5 years after receiving Lomecel-B TM (laromestrocel), compared to a 20 percent mortality rate observed from historical control data.

Negatives

The company has incurred recurring losses from operations since its inception, including a net loss of $5.0 million for the three months ended March 31, 2025.
The company expects to continue to generate operating losses for the foreseeable future.
There is substantial doubt about the company's ability to continue as a going concern.
The company's revenues decreased by 30% in Q1 2025 compared to Q1 2024.
The company's existing cash and cash equivalents are expected to fund operations only until late Q3 2025.

Risks

The company's cash position and need to raise additional capital could lead to difficulties in obtaining access to capital and may have a dilutive impact on investors.
The company's ability to continue as a going concern is dependent on securing additional financing.
Clinical trials may not demonstrate the safety and efficacy of product candidates.
The company may face difficulties in obtaining and maintaining regulatory approval of product candidates.
The company may not be able to obtain or protect intellectual property rights.
The company may need to hire additional personnel and may face difficulties in attracting and retaining such personnel.

Future Outlook

Longeveron anticipates needing additional funding by late Q3 2025 and is focused on advancing its HLHS and Alzheimer's disease programs, with a potential BLA filing for HLHS in 2026 if the ELPIS II trial is successful. The company is also seeking partnership opportunities and non-dilutive funding for its Alzheimer's disease program.

Management Comments

Following a successful Type C meeting with the FDA in August 2024 with respect to the HLHS regulatory pathway, the Company has begun ramping up its BLA enabling activities.
Following a positive Type B meeting with the U.S. FDA in March 2025 with respect to the Alzheimer's disease regulatory pathway, the Company is focused on seeking partnership opportunities and/or non-dilutive funding for the Alzheimers disease program, including a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial.

Industry Context

Longeveron operates in the competitive biotechnology industry, focusing on regenerative medicines. The company's efforts to develop cellular therapies for aging-related and life-threatening conditions align with the broader industry trend of exploring innovative treatments for unmet medical needs. The company faces competition from existing pharmaceutical and biotechnology companies.

Comparison to Industry Standards

It is difficult to compare Longeveron's results directly to industry standards due to its unique focus on cellular therapies and its stage of development.
Other biotechnology companies in similar stages of clinical development often face similar challenges related to funding, regulatory approvals, and clinical trial outcomes.
Companies like Mesoblast and Athersys are also developing cell therapies, but for different indications, making direct comparisons challenging.
Longeveron's reliance on grant funding is a common strategy among early-stage biotech companies, but it also introduces uncertainty regarding future funding availability.
The company's focus on rare pediatric diseases like HLHS aligns with the industry trend of targeting niche markets with high unmet needs, which can offer faster regulatory pathways and market exclusivity.

Stakeholder Impact

Shareholders may experience dilution if the company raises additional capital through equity offerings.
Employees face uncertainty due to the company's financial situation and potential need for cost reductions.
Patients with HLHS and Alzheimer's disease could benefit from successful development and approval of Lomecel-B.
Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

Complete enrollment in the Phase 2b ELPIS II trial for HLHS.
Seek strategic collaborations and non-dilutive funding for the Alzheimer's disease program.
Continue to analyze data from the CLEAR MIND trial.
Expand manufacturing capabilities to commercial-scale production.
Pursue potential additions to the product candidate pipeline through internal research and development and in-licensing.
Continue to expand the intellectual property portfolio.

Key Dates

Date	Description
October 9, 2014	Longeveron LLC was formed as a Delaware limited liability company.
December 15, 2014	Longeveron LLC was authorized to transact business in Florida.
November 20, 2014	The Company entered into an Exclusive License Agreement with UM (the UM License) for the use of certain Aging-related Frailty Mesenchymal Stem Cell (MSC) technology rights developed by our CSO at UM.
December 22, 2016	The Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (JMHMD), for the use of CD271 cellular therapy technology.
February 12, 2021	Longeveron LLC converted its corporate form from a Delaware limited liability company to a Delaware corporation, Longeveron Inc.
August 12, 2021	The underwriter received warrants to purchase 10,640 shares of Class A common stock as part of the Companys initial public offering (IPO).
November 8, 2021	The FDA granted Lomecel-B (laromestrocel) for the treatment of HLHS a Rare Pediatric Disease (RPD) Designation.
December 2, 2021	The FDA granted Lomecel-B (laromestrocel) for the treatment of HLHS an Orphan Drug Designation (ODD).
December 22, 2021	The resale of the shares of Class A common stock, and shares underlying the referenced warrants, were registered with the SEC via Form S-1 (File No. 333-261667), which was declared effective by the SEC.
August 24, 2022	The FDA granted Lomecel-B (laromestrocel) for the treatment of HLHS a Fast Track Designation.
November 16, 2022	The Company accounted for but had not issued 48,140 RSUs convertible to shares of Class A common stock, with an aggregate value of $ 207,000 as payment for accrued expenses under a consulting agreement with the CSO.
August 16, 2023	The Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of $ 52.50 for the period remaining through expiration.
October 2023	The Company entered into a registered direct offering of 501,821 shares of Class A common stock.
November 2023	The Company presented the improvement in HLHS survival following the Phase 1 ELPIS I clinical trial at the American Heart Association (AHA).
November 15, 2023	The Company filed a registration statement with the SEC on Form S-1 (File No. 333-275578) registering the resale these shares of Class A common stock, including the shares issuable upon exercise of the warrants, which was declared effective by the SEC on November 21, 2023.
December 2023	The Company entered into a registered direct offering of an aggregate of 145,020 shares of Class A common stock.
March 26, 2024	The Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a one-for-10 (1:10) basis.
February 21, 2024	The Company entered into a five-year Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes (Secretome), to address a spectrum of diseases driven by pathological processes , to manufacture, test, release, and supply Secretome with cardiac stem cells (the Product) to be used in Phase 1 and Phase 2 clinical trials (the Secretome Agreement).
April 2024	The Series A Warrants and Series B Warrants were amended to reduce the exercise price to $ 2.35 per share.
April 2024	The Company discontinued its clinical trial in Japan to evaluate Lomecel-B (laromestrocel) for Aging-related Frailty.
April 8, 2024	The Company commenced a public offering of up to 639,872 shares of the Companys Class A common stock, along with pre-funded warrants to purchase up to an aggregate 1,572,894 shares of Class A common stock (the Pre-Funded Warrants).
April 16, 2024	The Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of $ 2.35 per share in consideration for payment of $ 0.125 per new warrant and for the Companys agreement to issue new unregistered Class A common stock warrants to purchase up to 4,799,488 shares of Class A common stock at an exercise price of $ 2.35 per share, and which were immediately exercisable upon issuance.
April 18, 2024	The Company filed a registration statement with the SEC on Form S-1 (File No. 333-278995) registering the resale of an aggregate of 4,967,470 shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to 2,399,744 shares issuable upon the exercise of the Series C Warrants issued in the April 2024 warrant inducement transaction; (ii) up to 2,399,744 shares issuable upon the exercise of the Series D Warrants issued in the April 2024 warrant inducement transaction; and (iii) up to 167,982 shares issuable upon exercise of the warrants issued to the placement agent or its designees in the April 2024 warrant inducement transaction.
May 21, 2024	The Form S-1 was subsequently amended by the Company and declared effective by the SEC.
May 24, 2023	These shares were issued on May 24, 2023.
June 2024	All of the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction.
June 17, 2024	The Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining 1,697,891 shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of $ 2.35 per share in consideration for the Companys agreement to issue new unregistered Class A common stock warrants (the June Inducement Warrants), for payment of $ 0.125 per new warrant, to purchase up to an aggregate of 3,395,782 shares of Class A common stock at an exercise price of $ 2.50 per share and which were immediately exercisable upon issuance and have a term of twenty-four ( 24 ) months from the issuance date.
June 18, 2026	The June Inducement Warrants expire on June 18, 2026.
June 28, 2024	The Company filed a registration statement with the SEC on Form S-1 (File No. 333-280577) registering the resale of an aggregate of 3,563,764 shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to 3,395,782 shares issuable upon the exercise of the June Inducement Warrants and (ii) up to 167,982 shares issuable upon the exercise of the June placement agent warrants.
July 9, 2024	The FDA granted Regenerative Medicine Advanced Therapeutics (RMAT) Designation on July 9, 2024.
July 9, 2024	The Form S-1 was subsequently declared effective by the SEC on July 9, 2024.
July 10, 2024	A holder exercised Series C warrants for 50,000 shares of Class A common stock for cash (the July Series C warrant exercise).
July 10, 2024	Certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of 150,000 shares of Class A common stock for cash (the July 10 warrant exercise).
July 17, 2024	The FDA granted Fast Track designation on July 17, 2024, to Lomecel-B (laromestrocel) for the treatment of mild AD.
July 17, 2024	A holder of the June Inducement Warrants exercised the same to purchase 2,319,186 shares of Class A common stock for cash (the July 17 warrant exercise and together with the July 10 warrant exercise and the July Series C warrant exercise, collectively, the July warrant exercises).
July 18, 2024	The Company entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of 2,236,026 shares of our Class A common stock at a purchase price of $ 4.025 per share of Class A common stock and associated warrant (the July registered direct offering).
July 18, 2024	The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM.
July 19, 2024	The unregistered July private placement warrants have an exercise price of $ 3.90 per share, became exercisable on July 19, 2024, and expire on July 20, 2026.
July 20, 2026	The unregistered July private placement warrants have an exercise price of $ 3.90 per share, became exercisable on July 19, 2024, and expire on July 20, 2026.
August 2024	The Company had a positive Type C meeting with the FDA supporting the advancement of Lomecel-B (laromestrocel).
August 12, 2024	A registration statement was filed with the SEC on Form S-1 (File No. 333-281299) and declared effective on August 12, 2024, registering the resale of an aggregate of 2,565,392 shares of Class A common stock issuable upon exercise of certain warrants, including those issuable upon the exercise of the July private placement warrants, the July offering placement agent warrants issued to Wainwright, or its designees, and the July ordinary course placement agent warrants issued to Wainwright, or its designees.
September 2024	The Company entered into additional inducement letter agreements with certain holders of its existing Purchaser Warrants issued as part of the Companys 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $ 1.00 per share in consideration for the holders cash exercise of all Purchaser Warrants held by such holder on or before September 27, 2024.
October 2024	The Company entered into additional inducement letter agreements with the remaining holders of its existing Purchaser Warrants issued as part of the Companys 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $ 1.00 per share in consideration for the holders cash exercise of all Purchaser Warrants held by such holder.
October 2024	The brain volume results measured by MRI results from this trial also were presented at the poster presentation at AAIC.
October 2024	Additional data from the CLEAR MIND trial was presented as a late breaking poster presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain.
October 2024	Longeveron presented data at the Congenital Heart Surgeons' Society's 51st Annual Meeting.
February 13, 2025	Longeveron received notice from the World Health Organization (WHO) that the name laromestrocel for our Lomecel-B product has been adopted by the WHO and published in the International Nonproprietary Names ( INN) list 132.
March 4, 2025	The Company entered into stock option agreements with the CSO as part of a Cash-for-Equity Program.
March 20, 2025	Longeveron announced a positive Type B Meeting with the FDA supporting the advancement of Lomecel-B (laromestrocel) as a potential treatment for mild AD.
March 31, 2025	As of March 31, 2025, the Company had cash and cash equivalents of $14.3 million and working capital of approximately $12.6 million.
April 11, 2025	The Company entered into stock option agreements with the CSO as part of a Cash-for-Equity Program.
May 1, 2025	As of May 1, 2025, we have completed five U.S. clinical studies of Lomecel-B (laromestrocel): Phase 1 AD, Phase 1 HLHS, Phase 1/2 Aging-related Frailty (HERA Trial), Phase 2a AD (CLEAR MIND Trial), and Phase 2b Aging-related Frailty.
May 1, 2025	As of May 1, 2025, we have completed five U.S. clinical studies of Lomecel-B (laromestrocel): Phase 1 AD, Phase 1 HLHS, Phase 1/2 Aging-related Frailty (HERA Trial), Phase 2a AD (CLEAR MIND Trial), and Phase 2b Aging-related Frailty.
June 2025	The actual issuance of one stock option award granted to the Company's CSO is contingent on the approval of a stockholder proposal at the Company's annual meeting in June 2025 allowing for additional shares into the 2021 Incentive Plan.
July 1, 2025	Each stock option award will fully vest on July 1, 2025, provided that stockholder approval has been obtained at the Company's 2025 annual meeting of stockholders, to increase the pool of the shares available for awards under the 2021 Incentive Plan.
Late Q3 2025	The company anticipates needing additional funding by late Q3 2025.
2026	The company currently anticipates a potential BLA filing with the FDA in 2026 if the current ELPIS II trial in HLHS is successful.
December 31, 2027	ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027.

Keywords

Longeveron, Lomecel-B, HLHS, Alzheimer's disease, Clinical trial, BLA, RMAT, FDA, Financing, Cash runway, Biotechnology, Regenerative medicine

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.